Charnwood Discovery

Charnwood Discovery is an established, client-centric drug discovery CRO with over 25 years of experience, offering flexible, integrated project solutions from target identification to candidate selection. Its core capabilities span medicinal and synthetic chemistry, bioscience (including expertise in kinases, GPCRs, ion channels, and targeted protein degradation), and ADME/DMPK, supported by computational chemistry. The company's recent acquisition by Concept Life Sciences strengthens its service portfolio and market position as a partner of choice for biotech and pharma clients seeking external R&D expertise.

Integrated service platform combining Discovery Chemistry (medicinal, synthetic, analytical), Bioscience (assay dev, screening for Kinases, GPCRs, Ion Channels, TPD), ADME/DMPK, and Computer-Aided Drug Design (CADD). Expertise in modern techniques like photoredox catalysis and cyclic peptide discovery.

Competes with large global CROs (e.g., Charles River, LabCorp) and niche boutique discovery firms. Differentiates through integrated, end-to-end project delivery, expertise in specific target classes and novel modalities, and a client-partnership model within a mid-tier structure.